🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

British family doctors criticize change of plan on vaccine boosters

Published 2020-12-31, 11:44 a/m
© Reuters. People queue as they wait to receive a COVID-19 vaccine at London Bridge vaccination centre, amidst the spread of the coronavirus disease (COVID-19), in London
PFE
-

By Estelle Shirbon and Andrew MacAskill

LONDON (Reuters) - British doctors have said a government decision to delay giving a coronavirus vaccine booster shot to vulnerable patients who have already had a first dose will be distressing and disruptive, their trade union said on Thursday.

The government said on Wednesday it wanted to give a first dose to as many people as possible before starting to administer boosters at 12 weeks, in an effort to provide more people with a degree of protection more quickly.

But Dr Richard Vautrey, chair of the British Medical Association (BMA) committee for local family doctors, said it was "grossly and patently unfair to tens of thousands of our most at-risk patients to now try to reschedule their appointments".

For the newly approved vaccine developed by Oxford University and made by AstraZeneca being rolled out in Britain next week, the plan is consistent with a finding that waiting 12 weeks maximises protection against the virus.

But in the case of the Pfizer/BioNTech shot that is already being given, the manufacturer said the shot had not been evaluated on dosing schedules different from the recommended 21 days.

The BMA said scores of doctors had told it that the new approach would distress vulnerable patients and create logistical problems for healthcare staff.

"The BMA believes these are patients that have already been promised ... that they will receive a second dose of Pfizer (NYSE:PFE) vaccination next week; they have given their consent to receive it and, quite rightly, are expecting to have it," the BMA said.

More than 944,000 people had been given the Pfizer vaccine by Dec. 27, the health ministry said on Thursday.

The BMA said it would support any doctors who decided to honour existing booster appointments, and urged the government to provide a "scientifically validated justification" for its new approach.

In a joint statement, the chief medical officers from across the United Kingdom said they recognise that the request to re-schedule appointments will be difficult and will distress patients who were looking forward to being fully immunised.

© Reuters. People queue as they wait to receive a COVID-19 vaccine at London Bridge vaccination centre, amidst the spread of the coronavirus disease (COVID-19), in London

However, "in terms of protecting priority groups, a model where we can vaccinate twice the number of people in the next 2-3 months is obviously much more preferable in public health terms than one where we vaccinate half the number but with only slightly greater protection," they said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.